Key result
Pioglitazone treatment in women with polycystic ovary syndrome significantly improved insulin action and normalized elevated serum ApoJ levels compared to placebo, highlighting the role of the ApoJ-LRP2 axis in glucose homeostasis.
Why the study?
Crosstalk between the liver and skeletal muscle via hepatokines is vital for glucose homeostasis, but specific mediators regulating muscle glucose metabolism and insulin sensitivity remained to be identified.
Does the ApoJ-LRP2 axis regulate muscle glucose metabolism and insulin sensitivity?
Does the ApoJ-LRP2 axis regulate muscle glucose metabolism and insulin sensitivity?
The ApoJ-LRP2 axis is a novel endocrine circuit central to maintaining normal glucose homeostasis and insulin sensitivity, offering a potential new mechanistic target for insulin resistance.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for glucose management; leaves open therapeutic targeting of this hepatokine pathway.
Crosstalk between liver and skeletal muscle is vital for glucose homeostasis. Hepatokines, liver-derived proteins that play an important role in regulating muscle metabolism, are important to this communication. Here we identify apolipoprotein J (ApoJ) as a novel hepatokine targeting muscle glucose metabolism and insulin sensitivity through a low-density lipoprotein receptor-related protein-2 (LRP2)-dependent mechanism, coupled with the insulin receptor (IR) signaling cascade. In muscle, LRP2 is necessary for insulin-dependent IR internalization, an initial trigger for insulin signaling, that is crucial in regulating downstream signaling and glucose uptake. Of physiologic significance, deletion of hepatic ApoJ or muscle LRP2 causes insulin resistance and glucose intolerance. In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression. Thus, the ApoJ-LRP2 axis is a novel endocrine circuit that is central to the maintenance of normal glucose homeostasis and insulin sensitivity.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2020) studied Polycystic ovary syndrome and insulin resistance (n=27). Pioglitazone vs. Placebo was evaluated on Change in HOMA2-IR from pretreatment (p=<0.01). Pioglitazone treatment in women with polycystic ovary syndrome significantly improved insulin action and normalized elevated serum ApoJ levels compared to placebo, highlighting the role of the ApoJ-LRP2 axis in glucose homeostasis.
Synapse has enriched 10 related papers. Consider them for comparative context: